Purple Book product · Reference 351(a)
Lunsumio
mosunetuzumab-axgb
Dec 22, 2022
Approved
Reference 351(a)
License type
Rx
Marketing
None
Listed patents
Sourced from the FDA Purple Book · verified Jul 02, 2026
Key dates
Approval
Approval date of this BLA submission.
Dec 22, 2022
3 yr 7 mo ago
Today
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
Dec 22, 2029
in 3 yr 6 mo
Pharmaceutical detail
Strength
1MG/ML
Dosage form
Injection
Route
Intravenous
Presentation
Single-Dose Vial
Center
CDER
License number
1048
Product number
001
Submission type
Original
Supplement number
Not listed
Change type
Not listed
Reference product family
View full familyThis is the reference (originator) product. Its approved biosimilars and interchangeables are listed below.
1 additional BLA record for this product (other strengths or presentations) are in the same reference family.
Patent list
No patent-list records were published for this product. The Purple Book patent list reflects the statutory patent exchange under the BPCIA and is not exhaustive.
Source provenance
- advanced-searchAdvanced Search · Jul 02, 2026
- monthly-downloadMonthly download · Jul 02, 2026
Change history
- v4Jul 02, 2026
- v3Jul 02, 2026
- v2Jul 02, 2026
Frequently asked questions
Does Lunsumio have approved biosimilars?
Yes. 1 approved follow-on biologic reference Lunsumio in the Purple Book: Lunsumio Velo.
What is Lunsumio's BLA number?
Lunsumio is licensed under BLA 761263, held by Genentech, Inc..
When was Lunsumio approved by the FDA?
Lunsumio was approved by the FDA on Dec 22, 2022.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsThe list of FDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 & Inspection DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
